Cochlear Implantation in Patients With Neurofibromatosis Type 2: Variables Affecting Auditory Performance

被引:92
|
作者
Carlson, Matthew L. [1 ]
Breen, Joseph T. [1 ]
Driscoll, Colin L. [1 ,2 ]
Link, Michael J. [1 ,2 ]
Neff, Brian A. [1 ]
Gifford, Rene H. [3 ]
Beatty, Charles W. [1 ]
机构
[1] Mayo Clin, Dept Otolaryngol Head & Neck Surg, Sch Med, Rochester, MN 55905 USA
[2] Mayo Clin, Dept Neurol Surg, Sch Med, Rochester, MN 55905 USA
[3] Vanderbilt Univ, Dept Hearing & Speech Sci, Vanderbilt Bill Wilkerson Ctr, Nashville, TN USA
关键词
Acoustic neuroma; Cochlear implant; Hearing rehabilitation; Neurofibromatosis type 2; Vestibular schwannoma; ACOUSTIC NEUROMA; VESTIBULAR SCHWANNOMA; HEARING PRESERVATION; TUMOR SURGERY; REHABILITATION; RESECTION; RADIOSURGERY; MANAGEMENT; REMOVAL; NERVE;
D O I
10.1097/MAO.0b013e318254fba5
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective: To investigate cochlear implant performance outcomes among patients with Neurofibromatosis type 2 (NF2). Study Design: Retrospective case series, patient questionnaire, and systematic review of the literature. Setting: Tertiary academic referral center. Patients: All patients with NF2 having an anatomically intact ipsilateral cochlear nerve who underwent cochlear implantation (CI). Intervention(s): Cochlear implantation. Main outcome measures: Postimplantation audiometric performance and patient perceived benefit. Results: Ten patients met study criteria. The median duration of follow-up after CI was 42 months (mean, 46.9 mo; range, 12-97 mo). Five patients received previous microsurgical resection of their ipsilateral vestibular schwannoma, 4 underwent previous stereotactic radiosurgery, and 1 patient had no tumor treatment before CI. Nine subjects achieved sound awareness, 6 attained open-set speech recognition and 7 are daily users. Variables including prolonged auditory deprivation, cochlear ossification, unfavorable electrical promontory stimulation testing, and useful contralateral hearing were associated with poor cochlear implant performance. No statistical associations were found between open-set recognition capacity and previous tumor management strategy, surgical approach, or ipsilateral tumor size. Conclusion: Cochlear implantation is an attractive alternative to auditory brainstem implantation for hearing rehabilitation in patients with NF2. Approximately 70% of patients achieve open-set speech discrimination, many scoring at the ceiling of audiometric testing. Given a favorable risk profile and superior audiometric outcomes, CI should be strongly considered in patients with nonserviceable hearing who have an anatomically intact cochlear nerve, whereas auditory brainstem implantation should be reserved for patients with evidence of cochlear nerve loss. Akin to conventional cochlear implant recipients, prolonged hearing loss, unfavorable electrophysiological testing, and cochlear ossification may predict poor subject performance. Finally, useful hearing in the contralateral ear may present a barrier to daily device use.
引用
收藏
页码:853 / 862
页数:10
相关论文
共 50 条
  • [31] Comparing Speech Recognition Outcomes Between Cochlear Implants and Auditory Brainstem Implants in Patients With NF2-Related Schwannomatosis
    Dornhoffer, James R.
    Plitt, Aaron R.
    Lohse, Christine M.
    Driscoll, Colin L. W.
    Neff, Brian A.
    Saoji, Aniket A.
    Van Gompel, Jamie J.
    Link, Michael J.
    Carlson, Matthew L.
    OTOLOGY & NEUROTOLOGY, 2024, 45 (01) : 29 - 35
  • [32] Auditory brainstem implants for neurofibromatosis type 2
    Colletti, Liliana
    Shannon, Robert
    Colletti, Vittorio
    CURRENT OPINION IN OTOLARYNGOLOGY & HEAD AND NECK SURGERY, 2012, 20 (05) : 353 - 357
  • [33] Long-term analysis of ABI auditory performance in patients with neurofibromatosis type 2-related schwannomatosis
    Daoudi, Hannah
    Torres, Renato
    Mosnier, Isabelle
    Ambert-Dahan, Emmanuelle
    Liagre-Cailles, Amelie
    Smail, Mustapha
    Nguyen, Yann
    Ferrary, Evelyne
    Sterkers, Olivier
    Lahlou, Ghizlene
    Kalamarides, Michel
    ACTA NEUROCHIRURGICA, 2024, 166 (01)
  • [34] Ipsilateral cochlear implantation in patients with sporadic vestibular schwannoma in the only or best hearing ear and in patients with NF2
    Lassaletta, Luis
    Aristegui, Miguel
    Medina, Marimar
    Aranguez, Gracia
    Perez-Mora, Rosa M.
    Falcioni, Maurizio
    Gavilan, Javier
    Piazza, Paolo
    Sanna, Mario
    EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY, 2016, 273 (01) : 27 - 35
  • [35] Radiosurgical Treatment of Vestibular Schwannomas in Patients with Neurofibromatosis Type 2
    Phi, Ji Hoon
    Kim, Dong Gyu
    Chung, Hyun-Tai
    Lee, Joongyub
    Paek, Sun Ha
    Jung, Hee-Won
    CANCER, 2009, 115 (02) : 390 - 398
  • [36] Cochlear Implantation in NF2 Patients Without Intracochlear Schwannoma Removal
    Eitutis, Susan T.
    Jansen, Thijs
    Borsetto, Daniele
    Scoffings, Daniel J.
    Tam, Yu Chuen
    Panova, Tsvetemira
    Tysome, James R.
    Donnelly, Neil P.
    Axon, Patrick R.
    Bance, Manohar L.
    OTOLOGY & NEUROTOLOGY, 2021, 42 (07) : 1014 - 1021
  • [37] Facial Reanimation of Patients With Neurofibromatosis Type 2
    Vakharia, Kalpesh T.
    Henstrom, Doug
    Plotkin, Scott R.
    Cheney, Mack
    Hadlock, Tessa A.
    NEUROSURGERY, 2012, 70 (06) : 237 - 243
  • [38] Long-Term Effects of Bevacizumab on Vestibular Schwannoma Volume in Neurofibromatosis Type 2 Patients
    Killeen, Daniel E.
    Klesse, Laura
    Tolisano, Anthony M.
    Hunter, Jacob B.
    Kutz, Joe Walter, Jr.
    JOURNAL OF NEUROLOGICAL SURGERY PART B-SKULL BASE, 2019, 80 (05) : 540 - 545
  • [39] Strategy for the surgical treatment of vestibular schwannomas in patients with neurofibromatosis type 2
    Nowak, Arkadiusz
    Dziedzic, Tomasz
    Czernicki, Tomasz
    Kunert, Przemyslaw
    Morawski, Krzysztof
    Niemczyk, Kazimierz
    Marchel, Andrzej
    NEUROLOGIA I NEUROCHIRURGIA POLSKA, 2015, 49 (05) : 295 - 301
  • [40] Stereotactic radiosurgery for vestibular schwannomas in neurofibromatosis type 2 patients: a systematic review and meta-analysis
    Umberto Tosi
    Omri Maayan
    Anjile An
    Miguel E. Tusa Lavieri
    Sergio W. Guadix
    Antonio P. DeRosa
    Paul J. Christos
    Susan Pannullo
    Philip E. Stieg
    Andrew Brandmaier
    Jonathan P. S. Knisely
    Rohan Ramakrishna
    Journal of Neuro-Oncology, 2022, 156 : 431 - 441